Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Otsuka Pharmaceutical and UCB have agreed to focus their collaboration on the therapeutic area of central nervous system (CNS) disorders and to discontinue their collaboration in immunology.
Subscribe to our email newsletter
The companies will end their co-development and co-promotion agreement for certolizumab pegol in Japan followed by an agreed upon transition period.
UCB plans to further develop its immunology pipeline in Japan, starting with plans to file certolizumab pegol marketing authorization for rheumatoid arthritis (RA) patients in Japan.
Otsuka president and representative director Taro Iwamoto said Otsuka and UCB will build a strong sales base so that their compounds can contribute to a number of patients in need.
"Otsuka will strengthen the partnership with UCB in Japan while focusing on CNS compounds such as E Keppra, an anti-epileptic drug, and rotigotine, a dopamine agonist patch," Iwamoto added.